Skip to main content
. 2013 May 31;22(20):4074–4083. doi: 10.1093/hmg/ddt257

Figure 3.

Figure 3.

RG3039 minimally effects SMN levels in vivo. (A) Full-length (FL) and (B) SMNΔ7 SMN transcript levels in tissues from vehicle and RG3039-treated SMA mice at P10 6 h after the last dose, *P < 0.05, **P < 0.01 (brain: n = 13–15 per group, spinal cord: n = 5 per group, liver, heart, muscle: n = 10 per group). (C and D) Western blot analysis of SMN protein levels in (C) spinal cord and (D) brain extracts from vehicle and RG3039-treated SMA mice (n = 5 per group). (E and F) In vitro snRNP assembly analysis with radioactive U1 snRNA in (E) spinal cord or (F) brain extracts. U1 snRNA was immunoprecipitated with anti-SmB antibodies from each snRNP assembly reaction and analyzed by denaturing gel electrophoresis and autoradiography. (G and H) Quantification of U1 snRNA levels immunoprecipitated from snRNP assembly reactions with (G) spinal cord and (H) brain extracts from the experiments in (E) and (F) (n = 5 per group).